NCT05364307已完成不适用
Identification of Mild Cognitive Impairment (MCI) and Early Alzheimer's Disease (AD) Patients With a High Probability of Meeting Eligibility Criteria for a Therapeutic Alzheimer's Disease Clinical Trial (APHELEIA)
Global Alzheimer's Platform Foundation17 个研究点 分布在 2 个国家目标入组 1,555 人开始时间: 2022年6月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,555
- 试验地点
- 17
- 主要终点
- Determine number of patients eligible for therapeutic Alzheimer's Disease clinical trial
研究概览
简要总结
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for referral to a therapeutic AD clinical trial.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants and/or a legally authorized representative (LAR) must provide signed and dated informed consent and authorization to use personal health information in accordance with local and national guidance and regulations;
- •Male or female 50 to 90 years of age (inclusive) at the time of consent;
- •Participants must have a Mini-Mental State Exam (MMSE) score of 20 to 28 inclusive;
- •Progressive cognitive complaints must be reported by participant or caregiver;
- •Participants must be willing to comply with all procedures as outlined in the informed consent, including blood sampling, genetic testing, and storage of biospecimens for future research;
- •Fluency in the language of the tests used at the site;
- •Participants must be interested in participating in clinical research.
排除标准
- •Participants who, in the opinion of the Investigator, have serious or unstable medical conditions that would prohibit their completion of all prescreening procedures and data collection;
- •Participants who are currently enrolled in another clinical study.
- •Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;
- •Participants who have reported or have a known negative amyloid PET scan in the past 24 months;
- •Participants with history of stroke within 6 months of prescreening;
- •Participants with an uncontrolled seizure disorder, unexplained blackouts, OR history of a seizure within 6 months (subjects with a history of pediatric febrile seizure, benign rolandic epilepsy may participate);
- •Participants with a history or evidence of a malignancy within the 2 years prior to prescreening. Subjects with indolent malignancies (e.g., basal cell carcinoma or squamous cell carcinoma) or malignancies considered to be cured and not actively treated with anti-cancer therapy or radiotherapy are permitted to enroll;
- •Participants with known or suspected alcohol or drug abuse or dependence within 2 years of prescreening;
- •Participants with a reported suicidal attempt within 2 years of prescreening), or any unstable psychiatric symptoms (e.g., uncontrolled depression);
- •Participants who have participated in a clinical trial of any potential disease modifying AD treatment and received active drug within 6 months prior to prescreening;
- •Participants who have any neurological disorder affecting the central nervous system, other than AD, that may be contributing to cognitive impairment (e.g., Parkinson's disease, other dementias, multiple concussions or seizures) as deemed significant by the Investigator;
- •Participants with known history of hepatitis C virus, hepatitis B virus, human immunodeficiency virus (HIV) or other immunodeficiencies;
- •Participants that have previously been consented to this protocol;
- •Participants with a hypersensitivity to mAb treatments, protein derived from a mAb, or immunoglobulin therapy;
- •Participants with allergies to diphenhydramine, epinephrine, and methylprednisolone;
- •Participants who are direct employees or family members of direct employees of the participating investigators' sites;
- •Participants who are direct employees of the Sponsor;
- •Participants who, in the opinion of the Investigator, are unable to complete cognitive testing due to inadequate visual or auditory acuity.
结局指标
主要结局
Determine number of patients eligible for therapeutic Alzheimer's Disease clinical trial
时间窗: Throughout study completion, an average of 45 days
Participants with reported memory complaints and/or cognitive impairment will provide demographic information, clinical history, complete brief cognitive assessments, and provide blood-based biomarkers
次要结局
未报告次要终点
研究者
研究点 (17)
Loading locations...
相似试验
招募中
不适用
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and OverDepressionMild Cognitive ImpairmentNCT06011681Miro Health960
已完成
不适用
Early Detection of Mild Cognitive Impairment in Individual PatientsMild Cognitive ImpairmentMild Alzheimer's DiseaseNCT00243451Louisiana State University Health Sciences Center Shreveport34
撤回
不适用
Early Diagnosis of Patients With Mild Cognitive Impairment Through the Parameterization of Functional Tests.Mild Cognitive ImpairmentNCT03851198University of Malaga
招募中
不适用
Risk Model of Cognitive Impairment in DiabetesMild Cognitive ImpairmentType 2 Diabetes MellitusNCT05590442The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School500
招募中
不适用
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)BiomarkersMCI Conversion to DementiaNCT05697588Cuibai Wei，Clinical Professor900